Zhejiang Blood Products Institute

Zhejiang Blood Products Institute is a specialized biotechnology entity based in Hangzhou, China, focused on the research, development, and manufacture of plasma-derived therapeutics. The institute produces a wide range of essential blood products, including human albumin, intravenous immunoglobulin (IVIG), and specific coagulation factors such as Factor VIII for the treatment of hemophilia. In addition to therapeutic proteins, the organization is involved in the production of specialized hyperimmune globulins for rabies, tetanus, and hepatitis B. As a key player in the regional biopharmaceutical sector, it operates under strict GMP standards to ensure the safety and efficacy of life-saving blood derivatives. The institute serves as both a research hub for hematology-related biologics and a critical supplier for the Chinese healthcare system.